Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nutranomics, Inc. (NNRX)
Salt Lake City, UT, US
Nutranomics, Inc. focuses on the research, development, and marketing of health-focused nutritional products. Their extensive catalog features nearly 500 distinct dietary supplements, encompassing formulations of vitamins, minerals, herbal remedies, and probiotics. Beyond its product offerings, the company provides innovative services, such as its Nutritional Blood Analysis—a diagnostic tool enabling customers to observe their blood cells live on a video monitor—and the patented Assimilation Enhancing System, which is engineered to optimize nutrient absorption. Additionally, Nutranomics delivers comprehensive educational resources, including various forms of analysis, training programs, professional certifications, and group presentations, catering to both individuals and industry experts. The distribution of its products occurs globally through a network of sales representatives across North America and Asia, alongside availability in retail stores. Nutranomics, Inc. also maintains a strategic alliance with Terra-Formance, LLC. Established in 1995, the company is based in Salt Lake City, Utah.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +4,900.00% | +0.00% | +0.00% | +0.00% | +0.00% | +4,900.00% | -50.00% | -95.45% | -90.00% | -99.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+62.0% ★ Q2'23: +23.0% (vs Q2'22)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-133.3% Q2'23: +96.8% (vs Q2'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-199.7% Q2'23: +15.5% (vs Q2'22)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-145.0% Q2'23: -106.5% (vs Q2'22)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-105.1% Q2'23: -44.8% (vs Q2'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+62.2% Q2'23: +5,876.1% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-3.69× Q2'23: -6.07× (vs Q2'22)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 87-3463351 | 1.52B | 9.99% | — | 1.52B | — | 1.52B | OO | Nevada, United States | 2022-10-28 | ↗ |
| 2 | Maple Leaf Capital Management LLC, 52-2104785 | 1.52B | 9.99% | — | 1.52B | — | 1.52B | OO | Delaware, United States | 2022-10-28 | ↗ |
| 3 | Stephen M. Hicks | 1.52B | 9.99% | — | 1.52B | — | 1.52B | IN | Canada | 2022-10-28 | ↗ |
| 4 | Trillium Partners LP, 52-2104789 | 1.52B | 9.99% | — | 1.52B | — | 1.52B | OO | Delaware, United States | 2022-10-28 | ↗ |
| 5 | Lloyd Madison Capital Holdings, Inc. | 9.39M | 37.90% | 16.94M | — | 16.94M | — | HC | Nevada | 2015-07-31 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Geoffrey Bazegian | President & Chief Revenue Officer | — | male |
| Jonathan Bishop | Chief Executive Officer & Member of Advisory Board | — | male |
| Laura Riffel | Chief Operations Officer | — | female |
| Neil Zoller | Senior Vice President of Agricultural Supply Chain | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NNRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
